2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 - EULAR | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
EULAR
2021
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
Document
Analyser ce document